Averna Therapeutics
2 employees
Biopharm
Series A · $82.0M
Open positions (3)
Company details
Team Size2
IndustryBiopharm
Funding
Total raised
$82.0M
Last stage
Series A
Investors
OrbiMed
Total raised
$82.0M
Last stage
Series A
Investors
Roy Amariglio
Formerly a researcher at the Weizmann Institute of Science and an executive at Bayer; later an investor at OrbiMed. Identified the scientific opportunity that led to founding the company (then called Exsilio Therapeutics).
Tal Zaks
Former Chief Medical Officer at Moderna, where he led development of the COVID-19 vaccine. Joined Averna/Exsilio as Executive Chairman and Interim CEO, helping raise the Series A round.
Thomas M. Barnes
Appointed CEO in January 2025. Previously CEO of Orna Therapeutics and CSO/founding team member at Intellia Therapeutics. Holds a doctorate from the University of Cambridge.
No applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.